Inclusion Criteria:  ≥1 Healthcare Common Procedure Coding System (HCPCS) code (J code) or EMR note for treatment with brolucizumab during the index period (date of earliest code or EMR note = index date) ≥18 years old on the index date ≥1 Current Procedural Terminology (CPT) code for intravitreal administration on the index date  ≥1 International Classification of Diseases, Clinical Modification-9/10 (ICD-9/10) code for wet AMD in the 36 months prior to or on the index date  o Note: Off-label use of brolucizumab is not expected given payer access restrictions in the US.  ≥1 follow-up visit after the index date ≥1 VA assessment on the index date or within 90 days prior to the index date  Exclusion Criteria:  Use of brolucizumab prior to 10/8/2019 (e.g. clinical trials) Unknown laterality of the index eye on the index date